Cognitive profiles of vascular and neurodegenerative MCI by Nordlund, Arto
 
 
 
Cognitive profiles of vascular and neurodegenerative MCI 
 
 
 
 
Arto Nordlund 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institute of Neuroscience and Physiology 
Sahlgrenska Academy at Göteborg university 
 
 
 
 
 
 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
Table of contents 
ABSTRACT         4 
LIST OF PUBLICATIONS       5 
ACKNOWLEDGMENTS       7 
ABBREVIATIONS        8 
INTRODUCTION 
Cognitive science, cognitive psychology and cognitive functions  9 
Cognitive impairment       10 
Dementia        11 
Alzheimer’s disease       12 
Mixed and vascular dementia      13 
Neuropsychology of the dementia disorders    14 
Cognition and brain aging      15 
Mild cognitive impairment (MCI)     15 
MCI with vascular disease/VCI     17 
Biomarkers and MCI      19 
OBJECTIVES OF THE THESIS      19 
MATERIALS AND METHODS       
Inclusion, exclusion criteria and MCI subgrouping   20 
MCI with vascular disease     21 
Cerebrospinal fluid analysis     22 
Statistical analyses       22 
Neuropsychological assessment      24 
Speed and attention      25 
Memory and learning      26 
Visuospatial functions      27 
Language       27 
Executive functions      28 
RESULTS          
Study I         30 
Study II        30 
Study III        31 
Study IV        33 
Aetiology and subgroups     33 
Likelihood ratios, sensitivities and specificities   33 
Neuropsychological variables     34 
DISCUSSION         36 
Cognitive profiles of different types of MCI    36 
“Benign” MCI        37 
MCI and vascular disease      38 
MCI and AD biomarkers      38 
Young dementia patients      39 
Importance of the findings      40 
Limitations        40 
Future directions       41 
REFERENCES         42 
 
 
 4
Abstract 
 
The objective of the thesis was to investigate the cognitive profiles of 
different types of mild cognitive impairment (MCI) and follow their course 
over time.  Would it be possible to differentiate between “benign” and 
“malign” forms of MCI, and identify different dementia disorders in their 
prodromal stages by means of cognitive profiles? In study I consecutive 
MCI subjects (N=112) were assessed with a neuropsyhological test battery 
of 21 tests. When compared to healthy controls (N=35) MCI subjects had 
impairments in all cognitive domains (speed/attention, memory and learning, 
visuospatial functions, language and executive functions), which 
contradicted the prevailing view of MCI typically being memory 
impairment, ”amnestic MCI”. In study II the subjects were grouped by 
cerebrovascular disease. Subjects with significant vascular disease (N=60) 
performed overall worse on the neuropsychological test battery than those 
without vascular disease (N=60). The most clear-cut differences were seen 
on speed/attention and executive tests, and the conclusion was that there 
were similarities in the cognitive profiles of MCI with vascular disease and 
vascular dementia. In study III MCI subjects without vascular disease were 
grouped by concentrations of the Alzheimer-typical biomarkers total-tau (T-
tau) and beta-amyloid (Aß). Subjects with Alzheimer-typical concentrations 
of one or the other, or both biomakers in cerebrospinal fluid (N=73) 
performed worse on episodic memory and speed/attention tests than those 
with normal concentrations (N=73). When subjects were grouped into those 
with only high T-tau, only low Aß and both high T-tau and low Aß, those 
with both high T-tau and low Aß tended to perform slightly worse, while the 
other 2 groups performed quite similarly.  
In study IV 175 subjects were followed up after 2 years. Forty-four 
converted to dementia, all with impairment in several cognitive domains at 
baseline, and all but 2 had either vascular disease or Alzheimer-typical 
biomarkers. Single domain MCI – regardless of vascular disease and 
biomarkers – had a benign prognosis over 2 years. The combination of 
multiple domain amnestic MCI and vascular disease was the best predictor 
of mixed and vascular dementia, while multiple domain amnestic MCI and 
biomarkers was the strongest predictor of Alzheimer’s disease. 
MCI is a heterogeneous condition – the original purely amnestic MCI was 
very rare – with several aetiologies. The combination of cognitive profiles 
and aetiologies has the potential of making a crucial contribution in 
diagnosing dementia disorders at their earliest manifestations. 
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Introduction 
 
Cognitive science, cognitive psychology and cognitive 
functions 
 
A simple definition of cognitive science is the scientific study of the mind, 
or of thinking. It is an interdisciplinary science including the fields of 
psychology, philosophy, neuroscience, linguistics, anthropology, biology, 
and also computer science (Longuet-Higgins, 1987). There are several 
approaches to the study of cognitive science – symbolic, connectionist, and 
dynamic – of which cognitive psychology mainly uses the symbolic 
approach. Symbolic cognitive models are models intended to explain how 
some aspects of cognition are accomplished by sets of computational 
processes. A model is constructed for a specific cognitive task or class of 
tasks and constitutes a set of predictions that could be compared to data from 
human performance. Thus, the symbolic approach deals with models of 
mental – not brain regional – processes. The focus of this thesis will be on 
models of function and dysfunction within cognitive domains – speed and 
attention, memory and learning, visuospatial functions, language, and 
executive functions – rather than specific brain structures and locations of 
brain damage. 
 
The scientific questions cognitive modeling seeks to answer belong to 
cognitive psychology. Cognitive psychology is a school of thought in 
psychology that examines internal mental processes such as those mentioned 
above. Cognitive psychologists are interested in how people understand, 
diagnose, and solve problems, thus concerning themselves with the mental 
processes which mediate between stimulus and response (Neisser, 1967). 
According to the definition in the Swedish national encyclopedia the thought 
processes that accomplish this – handle our sensory input and memories – 
are cognitive functions. Thus, cognitive functions are very generally the 
thought processes necessary to deal with the demands and solve the 
problems of our every day life. Ulrich Neisser, who presented the term 
‘cognitive psychology’ in his book with that very title, published in 1967, 
provided a more elaborate definition. Neisser’s definition expands the 
concept beyond definitions such as “reasoning”, which often is found as a 
definition of cognition: 
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...the term "cognition" refers to all processes by which the sensory input is 
transformed, reduced, elaborated, stored, recovered, and used. It is concerned 
with these processes even when they operate in the absence of relevant 
stimulation, as in images and hallucinations... Given such a sweeping definition, it 
is apparent that cognition is involved in everything a human being might possibly 
do; that every psychological phenomenon is a cognitive phenomenon. Cognitive 
psychology is concerned with all human activity rather than some fraction of it.  
 
This very exhaustive definition brings cognition beyond the focus and 
approach of this thesis, which is one of cognitive neuropsychology; the 
cognitive functions necessary to process and handle the every day life, and 
how to measure those functions with tests. Still the definition is relevant in 
order to understand the role of cognition in psychology. Although Neisser 
claims that cognitive psychology is concerned with all human activity, he 
adds that perspectives other than the cognitive are valuable. Psychodynamic 
psychology, for instance, deals with motives and drives rather than with 
sensory input and how it is processed. Instead of asking how a man’s actions 
and experiences result from what he saw, remembered, or believed, the 
dynamic psychologists ask how they follow from his goals, needs, or 
instincts. The perspective of behavioral psychology is also different from 
that of cognitive psychology. While behaviorists are concerned with 
behaviour and how it is shaped by its consequences (i.e. conditioning), 
cognitive psychology acknowledges the existence of internal mental states, 
such as beliefs, wishes, desires and other motivating factors (Neisser, 1967). 
There are no absolute boundaries between the different traditions but their 
focuses certainly differ.  
 
 
Cognitive impairment 
 
Cognitive impairment has in the last decades got quite some attention. One 
conceivable reason for that is that we live in a society with increasing 
demands on cognitive functioning – faster and faster information exchange, 
rapid developments in technology, not least information processing – which 
could reveal even quite subtle cognitive deficits. Cognitive impairment is 
quite frequent in many states of ill-health, but often to some degree 
neglected and insufficiently surveyed, even though cognitive deficits may 
complicate treatment and follow-up. Significant cognitive impairment has 
been reported in Parkinson’s disease (Caballol, Marti, & Tolosa, 2007; 
Riedel et al., 2008), multiple sclerosis (Roca et al., 2008), diabetes 
(Luchsinger et al., 2007), heart failure (Vogels et al., 2007), neuropsychiatric 
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disorders (Chamberlain, Blackwell, Fineberg, Robbins, & Sahakian, 2005; 
Hale, Zaidel, McGough, Phillips, & McCracken, 2006; Loo, Hopfer, Teale, 
& Reite, 2004), chronic fatigue (Goshorn, 1998; Jason, Corradi, Torres-
Harding, Taylor, & King, 2005), chronic stress or distress (Oei, Everaerd, 
Elzinga, van Well, & Bermond, 2006; Wilson et al., 2007), depression 
(Elderkin-Thompson et al., 2003; Thomas & O'Brien, 2008), schizophrenia 
(Joyce & Roiser, 2007; Keefe & Fenton, 2007), HIV (Vance & Struzick, 
2007), cancer survivors who have undergone chemotherapy (Jansen, 
Miaskowski, Dodd, & Dowling, 2007; Vardy & Tannock, 2007), and even 
in sleep disorders (Massicotte-Marquez et al., 2008). These conditions may 
contribute or lead to more severe cognitive impairment and eventually 
promote the one condition that is characterized and defined by disabling 
cognitive impairment: dementia.   
 
 
Dementia 
 
Dementia is one of the most devastating and costly disorders affecting 
people. Dementia is a progressive decline in cognitive functions beyond 
what could be expected from normal aging, due to damage to, or disease in, 
the brain. Literally the Swedish word for dementia – demens – means out of 
one’s mind; from Latin’s de- “apart or away” and mens “mind”. Dementia is 
not a disease per se but a term for a non-specific illness syndrome which is 
caused by many different disease processes. The general criteria for 
dementia in DSM-IV (DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders), 1994), published by the American Psychiatric Association, is 
that there is impairment in several cognitive domains to such a degree that 
the person needs help or support in his or her everyday life. Thus, dementia 
does not affect only the patient, but also very much spouses, children and 
other close relations, whom the patient eventually will depend upon.  
 
The single greatest risk factor for dementia is old age. About 6% of the 
population over the established retirement age of 65 in Sweden are affected. 
The prevalence increases strongly with age; 1% of 60-65 year olds, 6% of 
75-79 year olds, and 45% of those aged 95 suffer from dementia (Wimo, 
Winblad, & Jonsson, 2007). According to some recent estimates, there are 
today about 30 million people in the world suffering from dementia, some 
160.000 of them in Sweden (Ferri et al., 2005). Considering that especially 
the western population live longer and longer, and with a fast increasing 
number of people over 60 in the world, it has been estimated that the number 
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will roughly double every 20 years, resulting in more than 40 million 
affected by 2020 and over 80 million by 2040 (Ferri et al., 2005). 
 
Dementia does not only cause the patient and the close relations serious 
suffering, but it is also an extremely costly condition. The direct costs of 
dementia have been estimated to 156 billion USD (about 1000 billion SEK) 
in 2003 (Wimo, Jonsson, & Winblad, 2006), an estimate that was doubled 
by 2005, to 315 billion USD (Wimo et al., 2007). Although highly 
developed countries spend over 90% of the money, they account for less 
than 40% the dementia cases (Wimo et al., 2006). Due to differences in 
culture, family patterns, economic strength, health care organization and 
financing, there is a great variability in how dementia care is provided, and 
thus the burden dementia causes the public finances. Nevertheless, there is 
no doubt that the burden is enormous and increases alarmingly, even in the 
less developed countries. Yet the indirect costs – production losses and 
premature mortality – are not included. Considering that the majority of 
persons with dementia are retired, those costs, however, can be expected to 
be relatively modest (Wimo et al., 2007). 
  
 
Alzheimer’s disease 
 
The most common dementia disorder is Alzheimer’s disease (AD), 
(Aggarwal & Decarli, 2007; Ferri et al., 2005) according to most reports it 
constitutes about 50% of all dementia cases (Ferri et al., 2005). This means 
that there are around 80.000 people suffering from AD in Sweden, a figure 
that has been estimated to increase to 100.000 by 2010 (Wimo et al., 2007). 
AD is an acquired neurodegenerative disease, the cause of which is 
unknown. Clinical signs of Alzheimer’s disease include progressive 
cognitive deterioration, often beginning with memory impairment. Reports 
on symptoms in all cognitive domains in the earliest stages of the disease, 
however, exist according to an extensive review; attention, visuospatial, 
language and executive deficits (Twamley, Ropacki, & Bondi, 2006). The 
onset of AD is gradual, with subtle cognitive decline – known as mild 
cognitive impairment – for years before the disorder can be considered to 
represent manifest dementia (Maioli et al., 2007; Morris et al., 2001).  The 
distinction between early and late onset AD is often made; whether the 
disease onset was before or after the age of 65. It is difficult to find reliable 
figures on the proportion of early onset AD. According to Mayo Clinic’s 
information on internet, early onset makes up 5-10% of all AD cases, while 
the Swedish Alzheimer society estimates the proportion to be 10-15%. Thus, 
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a reasonable estimate would be about 10%, which means that there are about 
8.000 AD patients under the age of 65 in Sweden. According to some reports 
the symptom profiles of early and late onset AD are different, with more 
“parietal” – language and visuospatial – symptoms and attention deficits in 
early onset, and a more generalized cognitive decline and confusion in late 
onset AD (Blennow & Wallin, 1992; Blennow, Wallin, & Gottfries, 1990; 
Reid et al., 1996). The duration of AD varies strongly depending on at which 
age the patient is diagnosed, with an average length of time from onset of 
symptoms to death in the range of 7 to 10 years for patients diagnosed in 
their 60s and 70s, to only about 3 years for patients diagnosed in their 90s 
(Brookmeyer, Corrada, Curriero, & Kawas, 2002) but it is not uncommon 
that patients live longer than that. 
 
 
Mixed and vascular dementia 
 
By definition, mixed dementia (MD) is a dementia syndrome caused by 
more than one disease process in the brain. The most common cause of MD 
is a combination of AD and vascular disease in the brain; cerebrovascular 
disease (CVD), compromising blood flow in the brain by small vessel 
disease, small infarctions or stroke (Langa, Foster, & Larson, 2004). MD can 
be diagnosed either on evidence of neurodegenerative dementia combined 
with CVD or a typical neurodegenerative symptomatology but also 
significant ischemic lesions on neuroimaging (Rockwood, 2003; Rockwood 
et al., 2000). There have been some discussion about the contribution of 
degenerative processes in vascular dementia (VaD), and vice versa, and the 
strict dichotomy between AD and VaD has been questioned. Recently, it has 
been suggested that “AD with CVD” or “mixed dementia” should be 
included in the clinical diagnosis of VaD (Nagata et al., 2007). There is no 
agreement about the prevalence and incidence of MD (Jellinger & Attems, 
2007). According to some, MD is probably one of the most common forms 
of dementia, since the risks of both neurodegenerative dementia and CVD 
increase with age (Langa et al., 2004; Nagga, Radberg, & Marcusson, 2004; 
Zekry, Hauw, & Gold, 2002). On the other hand others state that the 
prevalence of MD and VaD is decreasing due to better medical care 
(Manton, Gu, & Ukraintseva, 2005).  
 
Vascular dementia (VaD) is a heterogeneous clinical entity based on various 
expressions of vascular disease affecting the brain: small vessel disease as 
the primary vascular etiology, lacunar infarcts and ischaemic white matter 
lesions as the primary type of brain lesions (Erkinjuntti et al., 2000; Nagata 
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et al., 2007). VaD is, according to most studies, the second most common 
dementia disorder, but estimates on the prevalence of VaD vary – anything 
between 0.03% and 58% can be found in the autopsy literature (Jellinger, 
2007). According to a recent review, between 1% and 4% of all of 65 year 
olds suffer from VaD, and the prevalence probably doubles every 5-10 years 
(McVeigh & Passmore, 2006). Although these figures also vary, a 
reasonable estimate would be that VaD constitutes about 20% of all 
dementias (Aggarwal & Decarli, 2007). VaD seems to be slightly more 
common in some Asian countries, such as Japan and Korea, constituting 
25%-35% of all dementias (Jellinger, 2007). The perhaps most important 
distinction between different types of VaD made today is between poststroke 
dementia and subcortical VaD (Wallin, Milos, Sjogren, Pantoni, & 
Erkinjuntti, 2003). Poststroke dementia occurs with cognitive decline in 
close time relation to a transient ischemic attack. It has a sudden onset and 
stepwise course. The neuropsychological profile is diffuse, depending on the 
location of the brain insults. Subcortical VaD caused by small-vessel disease 
is probably the most common form of VaD, although the proportion figures 
vary between 37% and 67% (Roman, Erkinjuntti, Wallin, Pantoni, & Chui, 
2002). Subcortical VaD has a more gradual onset and progressive course, 
with a clinical picture typically characterized by psycho-motor slowing and 
executive deficits (Roman et al., 2002; Roman & Royall, 1999). Since AD is 
the most common dementia disorder, it also generates the greatest burden on 
public finances, but according to several reports, VaD contributes most 
significantly to the costs, since the health care costs of a VaD patient are 
markedly higher than those of an AD patient – according to one report twice 
as high (Fillit & Hill, 2002; Hill, Fillit, Shah, del Valle, & Futterman, 2005). 
  
 
Neuropsychology of the dementia disorders 
 
According to many reports, there is considerable overlap between the 
neuropsychological profiles of AD, MD and VaD (Almkvist, Backman, 
Basun, & Wahlund, 1993; Fahlander, Wahlin, Almkvist, & Backman, 2002; 
Groves et al., 2000), but reports on distinctive differences have also been 
published (Baillon et al., 2003; Graham, Emery, & Hodges, 2004; Kertesz & 
Clydesdale, 1994; Matsuda, Saito, & Sugishita, 1998; Schmidtke & Hull, 
2002). In summary, AD patients performed worse on memory and language 
tests, whereas VaD patients performed worse on motor, attention, 
visuospatial and executive tests. MD patients performed worse on a verbal 
executive test but performed otherwise similarly to AD patients. 
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Cognition and brain aging 
 
Even though age is the sole greatest risk factor for dementia, far from all old 
people will be affected by cognitive impairment – in fact, there are data 
suggesting that the prevalence of dementia decreases after the age of 95 
(Borjesson-Hanson, Edin, Gislason, & Skoog, 2004). In the last decades 
much effort has been put into developing concepts for describing how aging 
affects cognition. The concept of “successful aging” was first presented in 
The Gerontologist in 1961 (Havighurst, 1961) and has since been used to 
describe the 20% of all people who show practically no signs of cognitive 
decline and little somatic decline or ill-health with increased age. At about 
the same time the article “Senescent forgetfulness: benign and malignant” 
(Kral, 1962) was published, in which a distinction between normal 
forgetfulness and forgetfulness associated with brain disease was made. In 
the following decades cognitive decline associated with aging was mainly 
considered an expression of normal aging and explained by differences in 
general health and education (Anstey, Stankov, & Lord, 1993). Concepts 
such as age related cognitive decline (ARCD) (Craik & Salthouse, 1992) and 
aging-associated cognitive decline (AACD) (Levy, 1994) originally 
represented more benign forms of cognitive ageing. Eventually, however, in 
a number of studies individuals with the kind of cognitive decline these 
concepts were describing were found to be at a markedly increased risk for 
dementia (Celsis et al., 1997; Ritchie, Artero, & Touchon, 2001; Ritchie, 
Touchon, Ledesert, Leibovici, & Gorce, 1997). These findings led to the 
evolvement of diagnostic entities such as age-associated memory 
impairment (AAMI) (T. Crook, Bahar, & Sudilovsky, 1987; T. H. Crook, 
Larrabee, & Youngjohn, 1990) and mild cognitive impairment (MCI) 
(Petersen et al., 1997; Petersen et al., 1999), which were seen as potentially 
neurodegenerative conditions. MCI was even suggested to represent 
preliminary stages of dementia (Morris et al., 2001; Petersen, 2000). With 
symptomatic treatment available for AD – and potentially disease modifying 
treatments in clinical trials for both AD and VaD – the interest for 
identifying dementia disorders in their earliest manifestations has increased 
dramatically during the last decade. 
 
 
Mild Cognitive Impairment (MCI) 
 
In the second half of the last decade Mild Cognitive Impairment (MCI) 
(Petersen et al., 1997) emerged as the predominant target for studies on early 
signs and symptoms of dementia. MCI is conceptualized as a boundary or 
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transitional state between normal aging and dementia. In the original criteria 
MCI was defined as memory impairment with other cognitive domains 
relatively spared (Petersen et al., 1999). The memory impairment should be 
both subjective and objectively significant for age; confirmed by a 
significantly reduced memory test score. According to a number of studies, 
individuals with that kind of memory impairment, but with normal general 
cognitive function, converted to AD at a rate of 10-15% per year (Bowen et 
al., 1997; Guarch, Marcos, Salamero, & Blesa, 2004; Morris et al., 2001; 
Petersen et al., 1997; Petersen et al., 1999; Tierney et al., 1996). Although 
the focus of these studies was memory impairment, other cognitive 
impairments also were reported, for example naming deficits (Petersen et al., 
1999), impaired concept formation (Guarch et al., 2004) and executive 
impairment (Chen et al., 2000; Guarch et al., 2004). Eventually it was 
suggested that the risk of dementia, including AD, was significantly 
increased when other cognitive impairment was present, and that isolated 
memory impairment was not the best predictor of dementia. According to 
some studies, subjects with memory impairment alone were very rare and 
rarely progressed to dementia (Ritchie et al., 2001).  
  
These findings led to an amendment of the MCI criteria in 2001, the criteria 
were widened to encompass three MCI subgroups: amnestic (isolated 
memory impairment); multiple domains slightly impaired; single non-
memory domain impaired (Petersen et al., 2001). This model with three 
subgroups was, however, soon replaced by new criteria and a model with 
four subgroups. In 2004 the International Working Group on Mild Cognitive 
Impairment published a consensus report in which the following criteria 
were proposed for MCI: (i) the person is neither normal nor demented; (ii) 
there is evidence of cognitive deterioration shown by either objectively 
measured decline over time and/or subjective report of decline by self and/or 
informant in conjunction with objective cognitive deficits; and (iii) activities 
of daily living are preserved and complex instrumental functions are either 
intact or minimally impaired (Winblad et al., 2004). In accordance with the 
increasing heterogeneity of the concept, the MCI subgroups were increased 
with one; subjects could now be designated to one of four subgroups: 
amnestic; amnestic with multiple domains impaired: non- amnestic multiple 
domains impaired; non-amnestic single domain impaired. 
 
The notion of different aetiologies causing MCI was also introduced: 
degenerative, vascular, psychiatric and traumatic (Petersen, 2004). A model 
with MCI subtypes of different aetiologies representing different prodromal 
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dementia disorders was put forward. Amnestic MCI (aMCI) of degenerative 
aetiology was suggested to represent prodromal AD; amnestic MCI with 
multiple domains impaired (maMCI) of degenerative aetiology would also 
represent prodromal AD; maMCI of vascular aetiology would represent 
vascular dementia (VaD); non- amnestic MCI with multiple domains 
impaired (mdMCI) of degenerative aetiology dementia was suggested to be 
prodromal dementia with Lewy bodies (DLB); mdMCI of vascular aetiology 
VaD; non-amnestic MCI with single domain impaired would be prodromal 
frontotemporal dementia (FTD) or DLB (Petersen, 2004). Thus, it was 
suggested that a combination of clinical subtypes and aetiologies would be 
useful in predicting the specific dementia disorder that a person with MCI 
would progress to. 
 
There are numerous, discordant, reports on which MCI subtype constitutes 
the greatest risk of conversion to dementia. There is some agreement on that 
amnestic MCI – with or without other domains impaired – typically 
represents AD. Some studies report the risk of AD to be increased when 
domains other than memory also are impaired (Alexopoulos, Grimmer, 
Perneczky, Domes, & Kurz, 2006; Tabert et al., 2006) and conclude that 
pure aMCI has a more favourable prognosis than maMCI. Others report 
lower conversion rates for maMCI than aMCI and state that individuals with 
multiple domain or non-amnestic MCI ”include a substantial number of 
individuals who may not progress to dementia” and that neuropsychological 
variables other than memory are not instrumental to predict progression to 
dementia (Schmidtke & Hermeneit, 2008).    
 
 
MCI with vascular disease / Vascular Cognitive Impairment 
Cognitive disorders associated with vascular disease have lately been paid 
increased attention, for instance by the International Society for Vascular 
Behavioural and Cognitive Disorders (VAS-COG) (Wallin, Skoog, Kalaria, 
& Roman, 2004). According to some studies, vascular risk factors increase 
the risk of AD in MCI. In one study – although the best predictors of 
conversion to AD were found to be neuropsychological tests – AD 
converters tended to be more affected by vascular risk factors. The authors 
concluded that some vascular risk factors seem to promote progression from 
MCI to AD (Sepe-Monti et al., 2007). In another study vascular risk factors 
were reported to increase the risk of dementia, independent of MCI subtype 
(Ravaglia et al., 2006). In yet another study, the authors found that signs of 
vascular disease in the form of white-matter hyperintensities on brain 
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imaging were significantly associated with cognitive decline in MCI 
(Debette et al., 2007).  Also a differing conclusion has been reached: 
vascular disease does not contribute when predicting dementia in MCI 
(DeCarli et al., 2004).  
Most studies on MCI have focused on MCI as prodromal AD, but studies on 
MCI preceding other possible dementia disorders, such as VaD, have also 
been conducted. In many studies the prodromal stage of VaD is called 
vascular cognitive impairment (VCI) (Frisoni, Galluzzi, Bresciani, Zanetti, 
& Geroldi, 2002; Meyer, Xu, Thornby, Chowdhury, & Quach, 2002; 
Ravaglia et al., 2006). VCI refers to cognitive impairment caused by 
cerebrovascular disease and covers a whole spectrum of disorders, from 
minimally objectively identifiable deficits to VaD (Moorhouse & 
Rockwood, 2008; O'Brien, 2006). There is very little agreement about the 
clinical picture of VCI. According to one study on VCI, VaD is preceded by 
a stage of mild impairment, with similar, but less severe, cognitive deficits 
as in VaD (Sachdev et al., 2004), whereas the conclusion of others has been 
that the preclinical phase in VCI differs from not only AD, but is not similar 
to VaD either (Ingles, Boulton, Fisk, & Rockwood, 2007). The conclusion in 
other studies has been that VaD caused by subcortical disease often is 
preceded by progressive cognitive impairment, similar to the form of MCI 
preceding AD (Frisoni et al., 2002; Meyer et al., 2002). In one study the 
cognitive profile of MCI patients with prodromal AD (MCI-AD) was 
compared to that of MCI patients with vascular disease (MCI-vascular). 
MCI-AD and MCI-vascular did not differ on measures of memory, 
language, visuospatial skills/praxis or executive function. The groups had 
similar cognitive profiles, with deficits both on memory and other tests 
(Loewenstein et al., 2006). In another recent study MCI subjects were 
classified with amnestic MCI (a-MCI) and with multiple impaired cognitive 
domains MCI (mcd-MCI). The authors found that the mcd-MCI mainly had 
executive deficits and also significantly more vascular comorbidity and signs 
of vascular disease on brain imaging. All subjects who after 3 years had 
progressed to AD had previously been classified as a-MCI, and all subjects 
who had progressed to VaD had been classified as mcd-MCI (Zanetti et al., 
2006).  
 
Biomarkers and MCI 
 
Since 1995 two biochemical markers in the cerebrospinal fluid (CSF) for 
AD have emerged, total-tau (T-tau) and amyloid-ß42 (Aß42) (Andreasen, 
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Vanmechelen, Vanderstichele, Davidsson, & Blennow, 2003). Tau protein is 
located in the neuronal axons and the concentration of T-tau in the CSF is 
thought to reflect the intensity of neuronal degeneration in chronic 
neurodegenerative disorders (Blennow, 2004b). Aß42 is the major 
component of senile plaques and the decreased level of Aß42 in the CSF in 
AD may be caused by deposition of Aß42 in plaques, with lower levels 
being transported to CSF (Blennow, 2004a). Lately these biomarkers – 
increased levels of T-tau and decreased levels of Aß42 – have been used to 
predict AD in MCI subjects with some success  (Andreasen et al., 2003; 
Hansson et al., 2006; Ivanoiu & Sindic, 2005). Recently the biomarkers have 
even been used to predict MCI in seemingly healthy individuals (Li et al., 
2007). Some studies on MCI, examining the relation between CSF 
biomarkers and neuropsychological findings, have been conducted (Ivanoiu 
& Sindic, 2005; Schoonenboom et al., 2005). Both studies found elevated T-
tau concentrations primarily to be associated with poor performance on 
episodic memory tests, whereas decreased Aß42 concentrations were 
associated with poorer general neuropsychological performance. In a recent 
study, both patients with amnestic MCI and MCI with a dysexecutive 
syndrome had abnormal biomarkers and progressed to AD to approximately 
the same extent, with T-tau as the biomarker with the strongest predictive 
power (Herukka et al., 2007). 
 
 
Objectives of the thesis 
 
Although there have been considerable efforts made to promote MCI as 
prodromal AD or dementia, it is to date rather a loosely defined concept, 
referring to cognitive impairment that can be caused by a multitude of 
conditions. The prognosis of the individual MCI patient is often quite unsure 
and the question about possible treatment difficult. Finding sensitive and 
specific markers for the most common dementia disorders is crucial in order 
to be able to answer the patient’s rightfully worried questions about 
prognosis and possible treatment. This task is not only urgent for the 
individual patient but the society in large, considering the rapidly increasing 
strain on public finances cognitive ill-health cause, by for example stress and 
psychiatric ill-health, but especially dementia disorders. 
The overall objective of the thesis was to investigate the cognitive profiles of 
different types of clinically defined MCI and follow their course over time.  
Would it be possible to differentiate between “benign” and “malign” forms 
of MCI, and identify different dementia disorders in their prodromal stages 
by means of cognitive profiles? 
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The specific objectives were 
 To study which neuropsychological tests most clearly distinguish 
between a general population of clinically defined MCI subjects 
attending a memory clinic and healthy controls.  
 To examine whether the cognitive profile of MCI subjects with 
vascular disease differ from that of MCI subjects with no vascular 
disease. 
 To compare the neuropsychological profiles of MCI subjects with 
normal concentrations of total tau and Aß42 in CSF to MCI subjects 
with an AD-typical pattern, i.e. increased and decreased 
concentrations of these biomarkers.  
 To investigate the predictive value of different MCI subtypes and 
aetiologies for conversion to AD, mixed dementia and VaD, and to 
study which neuropsychological tests strongest predicted conversion 
to dementia. 
 
 
 
Materials and methods 
 
Inclusion, exclusion criteria and MCI subgrouping 
 
The subjects in the studies were recruited from patients attending a memory 
clinic at Sahlgrenska university hospital. The memory clinic started in 1992, 
and has since grown to be the major activity of the neuropsychiatric clinic, 
with 2400 new patients between 2000 and 2007. See table 1 for an overview 
of the studies and table 2 for demographic data for the participants. The 
diagnoses of MCI were made in diagnostic conferences by experienced 
clinicians, specifically for research purposes, following the 2004 MCI 
criteria (Winblad et al., 2004). The neuropsychological results were not used 
for diagnostic purposes; the diagnoses were based on information about 
medical history and a neuropsychiatric examination by means of checklists 
for cognitive symptoms: stepwise comparative status analysis (STEP)  
(Wallin et al., 1996), cognitive variables 13-20 (memory disturbance; 
disorientation; reduced abstract thinking; visuospatial disturbance; poverty 
of language; sensory aphasia; visual agnosia; apraxia) for basic dementia 
related cognitive symptoms; I-Flex, which is a short form of the Executive 
interview (EXIT) (Royall, Mahurin, & Gray, 1992) (items: number-letter 
task; word fluency; anomalous sentence repetition; interference task; Luria 
hand sequences; counting task) for frontal lobe symptoms; and mini-mental 
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state examination (MMSE) (Folstein, Folstein, & McHugh, 1975) and 
clinical dementia rating (CDR) (Morris, 1997) as global measures of 
functioning. The information for CDR was gathered from both the subject 
and an informant. For the diagnosis of MCI, subjective and objective 
(verified by an informant) anamnestic evidence for progressive cognitive 
impairment for more than 6 months was required. A positive outcome on 
STEP, EXIT, MMSE or CDR was also required. Subjects without a positive 
outcome on the cognitive checklist were not included, since their cognitive 
impairment was considered merely subjective, neither were subjects with 
more than 2 positive outcomes on STEP or a score below 25 on MMSE – or 
both – as they were considered to fulfil criteria for dementia. Subjects with 
major depressive and other severe psychiatric disorders, and substance abuse 
were excluded. Minor depressive symptoms and mild anxiety were allowed. 
 
The healthy controls were mainly recruited from senior citizen organisations 
and via information meetings on dementia. A few controls were spouses of 
subjects in the study.  
Inclusion criteria for controls were that they should be physically and 
mentally healthy and not experience or exhibit any cognitive impairment or 
vascular disease. All controls were thoroughly interviewed about their 
somatic and mental health by a research nurse before being screened for the 
study. Before they were included, they underwent a thorough physical, 
neurological and neuropsychological examination as well as an MRI scan, in 
order to exclude cognitive impairment and cerebrovascular disease.  
 
 
MCI with vascular disease 
 
MCI subjects with vascular disease were identified as follows: occurrence of 
(i) symptoms of MCI, 2 (or more) expressions of vascular disease (arterial 
hypertension, cardiac insufficiency, angina pectoris, cardiac rhythm 
disturbance, cardiac infarction, TIA, stroke, hyperlipidemia, diabetes 
mellitus or peripheral vessel disease) and findings on MRI due to vascular 
disease: moderate white matter changes according to a 4 grade scale 
(Scheltens et al., 1998) and/or several lacunes (more than two) and/or signs 
of infarctions on MRI (ii) symptoms of MCI, TIA and/or stroke and 
moderate white matter changes/lacune formations, and/or signs of infarction 
on MRI.   
 
 
 
 
 22
 
Cerebrospinal fluid analysis 
 
CSF samples were collected in polypropylene tubes, and were stored at –80º 
C pending biochemical analyses, without being thawed and re-frozen. CSF 
samples were taken at baseline in all MCI cases and controls. CSF T-tau was 
determined using a sandwich enzyme-linked immunosorbent assay (ELISA) 
constructed to measure total tau (Blennow et al., 1995). CSF Aß42 was 
determined using an ELISA constructed to measure Aß42 (Andreasen et al., 
1999). For cut-off values, the CSF concentrations of the control group were 
used. The T-tau of the control group was 291 ± 102 pg/ml which was 
significantly lower than in the MCI group, 416 ± 328 pg/ml (p<0.001). The 
CSF Aß42 of the control group was 750 ± 224 pg/ml, which was 
significantly higher than in the MCI group, 622 ± 197 pg/ml (p=0.001). 
Using the 0.90 fractile of the control group values as a cut off, (Chemistry, 
1987), the cut-off for T-tau was 405 pg/ml and for Aß42 465 pg/ml.  
 
Statistical analyses 
Several variables were found to be skewed and were rescaled as appropriate 
to approximate normality before being entered in the statistical calculations. 
The data are presented as means ± standard deviation of the raw data. In 
study I group comparisons were made with the t test and the Mann–Whitney 
U test (SPSS). Corrections for 
multiple comparisons were made by the Bonferroni Holm method. In study 
II group comparisons were made with analysis of variance (ANOVA) and 
Pearson Chi-Square (SPSS). Multiple comparisons were adjusted for with 
Bonferroni correction. 
Due to differences in age and education between the MCI groups in study 
III, those variables were entered as covariates in the statistical analyses of 
neuropsychological data, and group comparisons were made with ANCOVA 
(SPSS). Multiple comparisons were adjusted for with Sidak correction. In 
study I, II and III a principal components analysis (PCA; SIMCA-P 10.0) 
was performed on the data from the test battery, i.e including all test 
variables (Eriksson, Johansson, Kettaneh-Wold, Wikström, & Wold, 2002). 
Significance of the models was determined by cross validation. Each PCA 
resulted in one significant latent variable that summarized the constituent 
neuropsychological test variables. In study I, II and III we report Eta-squared 
(η²) as an index of effect size in the parametric statistical tests, which can 
vary between 0 and 1. In study IV Partial Least Squares Discriminant 
Analysis (PLS-DA) was used to analyze the data (Eriksson, Johansson, 
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Kettaneh-Wold, & Wold, 2001), employing SIMCA-P 10.0 software 
(Umetrics AB, Umeå, Sweden). The PLS-DA, which can be regarded as a 
form of logistic regression, was used to separate subjects with or without 
dementia on the basis of their cognitive functioning in the multiple 
neuropsychological tests. The technique creates of a set of principal 
components, whose significance is determined by cross-validation, and 
which summarize the original cognitive variables on the basis of their 
covariances. The components are rotated in such a way as to separate the 
specified groups as much as possible. We present the parameter variable 
influence on projection (VIP) which succinctly summarizes the important 
independent variables. Predictors with a VIP ≥ 1 are very influential for the 
model as a whole (Eriksson et al., 2001). 
 
 
Table 1  Overview of the data collection and subjects in the studies 
Study Period of data  
Collection 
Number of  
Controls 
Number of 
MCI 
Group comparisons 
I Jan 2000- 
Oct 2002 
35 112 Controls – MCI 
II June 2000- 
Dec 2003 
60 120 Controls - MCI without vascular 
disease - MCI with vascular 
disease 
III May 2000- 
Dec 2005 
50 146 Controls - MCI with AD 
biomarkers - 
MCI with normal biomarkers 
IV Mar 2000- 
Apr 2007 
0 175 Stationary MCI - MCI converted 
to dementia 
 
 
Table 2   Overview of demographic data in the studies  
Study Gender 
Male/female 
Age Education MMSE Main statistical 
Method 
I 
 
49/63 64 ± 8 11.6 ± 3.5 28.5 ± 1.5 Student’s t-test 
II 
 
50/60 66 ± 7 11.5 ± 3.6 28.3 ± 1.5 ANOVA 
III 
 
66/80 63 ± 7 12.0 ± 3.2 28.5 ± 1.3 ANCOVA 
IV 73/102 64 ± 8 12.0 ± 3.5 28.4 ± 1.5 Likelihood ratios, 
Sensitivities and specificities 
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Neuropsychological assessment 
 
The cognitive profiles of MCI are defined by cognitive test scores – 
neuropsychology – which makes neuropsychology the central theme of this 
thesis. There is an overwhelming body of evidence that neuropsychological 
assessment is the most important tool for identifying neurocognitive 
disorders at their earliest manifestations (Marcos et al., 2006; Nelson & 
O'Connor, 2008; Tabert et al., 2006; Twamley et al., 2006). Although there 
is no real agreement on which specific tests should be used for different 
patient groups, the American Academy of Neurology (AAN), has published 
guidelines for what a neuropsychological assessment should comprise. 
According to AAN an assessment should cover the cognitive domains speed 
and attention, learning and episodic memory, visuospatial functions, 
language and executive functions and intelligence/general cognitive 
capacity. Within each cognitive domain several aspects of function should 
be assessed, in order to obtain as complete a picture as possible of the 
cognitive status of a subject. As described below, and presented in table 3, 
the neuropsychological battery used for this thesis is well in agreement with 
those guidelines. 
 
Intelligence should not be considered a cognitive domain in the same sense 
of the concept as the other domains. According to AAN it is, however, 
important to obtain a measure of intelligence, or rather general cognitive 
capacity, as an initiating point for the neuropsychological examination. It is 
essential to have something to contrast the results against: is the present 
result what can be expected from this patient or is there reason to suspect 
that the result indicates impaired function for the patient, considering his or 
her general capacity? The most widespread measure of intelligence is 
Wechsler’s Adult Intelligence Scale (WAIS) (Wechsler, 1981), which a few 
years ago was published in yet another revised edition, WAIS-III, in a 
number of languages, among them Swedish. WAIS is, however, quite 
extensive and thus time consuming to administer. Furthermore, WAIS may 
for subjects with MCI be misleading as a measure of general cognitive 
capacity, since performance on a number subtests will be influenced by 
impairment within any cognitive domain. Hence, simpler measures of 
general cognitive capacity have been developed for patients with cognitive 
impairment, so called resistant, or “hold”, tests. One of the most frequently 
used nonverbal brief tests of intelligence, Raven’s progressive matrices 
(Raven, 1965), was used. It exists in three versions and the shortest and 
easiest version, coloured matrices, which is intended for children, elderly 
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persons and persons with cognitive decline, was used in the studies in this 
thesis. Below, the other tests in the neuropsychological test battery are 
described. 
 
 
Speed and attention 
 
A definition of speed and attention would be the cognitive function by which 
a person concentrates on and processes some features of the environment to 
the relative exclusion of others. Basic psychomotor and processing speed, 
and being able to steer one’s attention are most basic cognitive functions; 
much of all other cognitive functioning presupposes that we are able to 
process information and focus our attention as needed. If you are unable to 
focus your attention to the task at hand, you will fail the task, regardless of 
what the nature of the task is.  Digit Span from WAIS (Wechsler, 1981) is a 
measure of attention span and working memory. In Digit Span the patient is 
to repeat series of digits, the span of which increases. First the digits are 
repeated forward and then backward. Digit Symbol is another of  the WAIS 
subtest, which is quick and easy to administer – for 90 or 120 seconds 
(depending on which version is used) the patient is to enter symbols in boxes 
on a sheet of paper according to a symbol key – and provides a measure of 
focused attention and speed. The 2 other tests in this domain are Trailmaking 
A and B (Reitan, 1985). In the A version the patient is to draw lines between 
circles containing numbers 1 through 25 on a sheet of paper, as quickly as 
possible. Thus, the test provides a measure of survey ability and speed. In 
the B version the task has been made more complex: the patient is now 
given a sheet of paper with both numbers and letters. The patient is to 
alternate between numbers and letters; to draw a line from 1 to A, to 2 to B 
and so forth. Part B provides a measure of more complex, alternating, 
attention functions.  
 
 
Memory and learning 
Human memory consists of multiple, interacting, systems. In the 1970s, the 
grand old man of memory research, Endel Tulving, presented his model for 
memory, with the distinction between semantic and episodic memory 
(Tulving, 1987). These memory systems constitute the broader category of 
declarative memory: memory of factual information. Tulving described 
semantic memory as knowledge of grammar, vocabulary, and concepts. 
Semantic memory allows us to understand ideas, solve problems, and 
comprehend language. Episodic memory is the memory of events or 
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episodes that one has experienced personally, at a particular time and place. 
Later, procedural memory was added to the model. Procedural memory is 
the unconscious memory responsible for our ability to perform tasks, for 
example swimming or riding a bike, which are forms of procedural 
knowledge. Procedural memory differs from declarative memory in that 
declarative memory is a conscious memory of facts, while procedural 
memory is unconscious and responsible for skills and habits that become 
automatic. 
The memory system that first and foremost is impaired in neurocognitive 
disorders – with the exception of some very rare conditions – is episodic 
memory. Semantic memory is often impaired in early AD, but not as 
markedly as episodic memory in the mild stages (Balthazar, Martinelli, 
Cendes, & Damasceno, 2007). There is a wide variety of episodic memory 
tests available, most of them verbal. One of the most frequently used tests 
in the world is Rey Auditory Verbal Learning Test (RAVLT) (Geffen, 
Butterworth, & Geffen, 1994). RAVLT consists of 15 high imagery nouns 
that are read to the patient five times. After each reading the patient is to 
repeat as many words as possible. Next, another 15 word distraction list is 
read to the patient, after which he/she is asked to repeat the first list once 
more. After another 30 minutes of distraction the patient is asked to try to 
recall the first word list once more. Lastly, the patient is asked to identify 
the words he/she is unable to recall from a recognition list. Thus, the test 
provides information about learning capacity – whether the patient is able 
to increase the number of words recalled as the word list is repeated – as 
well as recall and recognition. Another very widely used verbal memory 
test is Wechsler’s Logical Memory (WLM) (Wechsler, 1987). Two short 
stories are read, which the patient is to repeat immediately and after 30 
minutes of distraction. WLM is more about being able to recall and retell 
an event than learning capacity.  
Rey Complex Figure (RCF) recall is a non-verbal memory test (Meyers, 
1995). In RCF the patient is to copy a complex geometric figure, not 
knowing that he/she is performing a memory task. After a few minutes of 
distraction the patient is asked to draw the figure from memory. The 
memory task is repeated after yet 30 minutes of distraction. One 
disadvantage of RCF is that patients who have visuospatial deficits often 
have difficulty processing the figure in its entirety, which leads to memory 
performance not equivalent to their actual memory capacity. Face 
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recognition consists of 15 pictures of faces that the subject is to identify 
from 30 immediately after having seen the target faces. 
 
 
Visuospatial functions 
 
Visuospatial functions refer to thought processes involving visual and spatial 
awareness, which include comprehending and conceptualising visual 
representations and spatial relationships when performing a task. The most 
basic visuospatial function is spatial perception: to be able to distinguish an 
object from its background. A test battery, Visual Object and Space 
Perception (VOSP), has been developed for the purpose of measuring that 
very function (Binetti et al., 1998). In the Silhouettes subtest from the VOSP 
battery the patient is to identify 30 silhouettes representing animals and 
everyday objects. RCF copying measures spatial orientation; to perceive 
how the parts constitute the whole shape of what you see, and to interpret the 
parts based on how they contribute to the whole (Meyers, 1995). The third 
test in this domain is Block Design from WAIS (Wechsler, 1981), which is 
considered a measure of spatial construction. Block Design, however, is also 
sensitive to speed/attention and executive deficits and thus not as 
specifically visuospatial as the previously mentioned tests (Nordlund et al., 
2007).  
 
 
Language 
 
The definition linguists use for language is symbolic representation; that a 
symbol – whether it is visual, auditory, or tactile – represents something 
other than itself, according to set rules. According to this definition language 
is uniquely human, and probably the most complex system that exists. 
Considering the complexity of language, several aspects need to be assessed: 
Token Test, part V, is a test of language comprehension. It consists of 22 
commands that the patient is to follow using circles and squares in five 
different colours (Bandera, Capitani, Della Sala, & Spinnler, 1985). Token 
Test is very easy to use normatively, since a healthy adult is expected to 
manage all 22 commands. Assessment of Subtle Language Disorders 
(ASLD) Repetition is a test constructed to assess higher order language 
(Crosson, 1996). It consists of 10 sentences of increasing length that the 
subject is asked to repeat verbatim (Lezak, 1995). The ASLD logical 
grammar sub test is a test of complex language comprehension. It consists of 
10 sentences of increasing complexity, in which the subject is to follow an 
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instruction or answer a question (Crosson, 1996). Boston Naming Test 
(BNT) is a naming test, which consists of 60 drawings of different objects, 
from some very high frequency (bed, tree) to some quite low frequency 
(sphinx, abacus) (Kaplan, 1983). Similarities from WAIS (Wechsler, 1981) 
is used for measuring abstract aspects of language. The patient is asked to 
explain the similarity between, for example, a seed and an egg, and an 
enemy and a friend. Word fluency FAS (or Controlled Oral Word 
Association Test as it is also called) is used for assessment of executive 
aspects of language (Crossley, D'Arcy, & Rawson, 1997). In FAS the patient 
is to try to produce as many words as possible beginning with F, A and S in 
one minute for each letter. 
 
 
Executive functions 
 
In short, executive function is goal directed behaviour; optimizing one’s 
performance in order to reach a certain goal. This performance has by Lezak 
(2004) been described as having four components: (1) volition (2) planning 
(3) purposive action, and (4) effective performance. Thus, executive 
function is not so much about what you do, but that and how you do it. Dual 
task is a test of divided attention in which the subject is asked to draw 
crosses in boxes on a sheet of paper while simultaneously repeating series of 
digits (Della Sala, Baddeley, Papagno, & Spinnler, 1995). Wisconsin Card 
Sorting Test (WCST) is probably the best known and most frequently used 
executive test, also in dementia research (Paolo, Axelrod, Troster, 
Blackwell, & Koller, 1996). WCST consists of a number of cards with one 
to four symbols in different colours. The patient’s task is to conclude the 
right principle for putting the cards in one of four piles. In Stroop Colour 
Word Test the patient is to name the colours a number of words are written 
with, and thus inhibit the automated response, which is to read the word. The 
short Victoria version, which is presented in Spreen & Strauss was used 
(Spreen & Strauss, 1998). Another test presented in Spreen & Strauss test 
that was constructed for assessing judgment – an essential aspect of 
executive function – is Cognitive Estimation Test. The test consists of ten 
questions about information that most people have a fair notion of, but 
probably do not know the exact answer to (how high is the Eiffel tower; how 
long is the spine of an average male). Thus, the patient is to make a 
reasonable estimate. A contribution of our clinic and the Institute of 
Neuroscience and Physiology at Sahlgrenska Academy to the battery is 
Parallel Serial Mental Operations (PaSMO), which is a measure of mental 
control. The patient is first asked to rattle off the alphabet as quickly as 
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possible. Next he or she is asked to rattle off the alphabet once more but this 
time also state the number of the letter, i.e. A-1, B-2, C-3 and so forth. Thus, 
it is a measure of mental control and tracking.  
 
 
Table 3  Cognitive domain    Specific functions and neuropsychological tests 
Speed and attention Digit Symbol (WAIS-R), Trail making A and B, Attention 
span/working memory: Digit Span (WAIS-R) 
Learning and memory Verbal episodic memory: RAVLT, Wechsler’s Logical Memory 
(WMS-R),      Non-verbal episodic memory: Rey Complex Figure 
Visuospatial functions Perception: Silhouettes (VOSP), Spatial organisation: Rey Complex 
Figure copy, Construction: Block Design (WAIS-R) 
Language  Comprehension: Token Test, subtest V, Comprehension and 
repetition: ASLD repetition, Confrontation naming: Boston Naming 
Test, Abstraction: Similarities (WAIS-R) Word Fluency: FAS  
Executive functions Divided attention: Dual Task, Planning and inference: WCST-CV64, 
Distractibility: Stroop Test, Victoria version,  Judgement and 
calculation: Cognitive Estimation Test, Mental control: PaSMO 
 
 
 
 
 
 
 
 
Results 
 
Study I 
 
The objective of the study was to find out which neuropsychological tests 
most clearly distinguish between MCI and healthy controls. The participants 
consisted of 35 healthy controls with a mean age of 68 ± 5 years and 112 
consecutive MCI subjects with a mean age of 65 ± 8 years. The results 
showed that MCI is a heterogeneous condition, the MCI subjects were 
impaired in all cognitive domains, when compared to the controls. The 
original,”traditional” amnestic MCI with isolated memory impairment was 
very rare, only 2/112 subjects (1.7%) had such a cognitive profile. The 
cognitive domains in which most MCI subjects had significantly impaired 
results were language and executive function, episodic memory being the 
third domain. About one out of six (17%) subjects did not show any 
impaired results, as compared to their age norms. These subjects were 
younger, better educated and performed better on test of general cognitive 
capacity than the other subjects.  
WAIS-R=Wechsler’s Adult Intelligence Scale-Revised, RAVLT=Rey Auditory Verbal Learning Test, WMS-
R=Wechsler’s Memory Scale-Revised, VOSP=Visual Object and Space Perception, ASLD=Assessment of 
Subtle Language Deficits, PaSMO=Parallel Serial Mental Operations, WCST-CV64=Wisconsin Card Sorting 
Test-Computer Version 64 (short version) 
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Study II 
 
The objective of the study was to find out whether the cognitive profile of 
MCI subjects with vascular disease differ from that of MCI subjects with no 
vascular disease. The participants consisted of 60 healthy controls, mean age 
66 ± 5 years, and 120 age matched MCI subjects: 60 without vascular 
disease (MCI-nov), mean age 66 ± 7 years, and 60 with vascular disease 
(MCI-vas), mean age 67 ± 7 years.      
The healthy controls performed better than the 2 MCI groups on the 
cognitive test battery. Cognitively, controls, MCI-nov and MCI-vas 
constituted three distinct groups, both in terms of overall performance, 
according to the Principal Components Analysis (PCA) and cognitive 
profiles. The most clear-cut differences between MCI-nov and MCI-vas 
were seen on tests of speed/attention and executive functions, as illustrated 
in table Study II, in which the significant test results and the memory tests 
are presented.  
 
 
Study II                      Means and significance levels for the test battery 
 Controls MCI-nov MCI-vas η² Controls vs 
MCI-nov 
adjusted  
p value 
MCI-nov vs  
MCI-vas 
adjusted  
p value 
Speed and attention       
Trail Making B (sec) 85.9 ± 25.9 107.4 ± 52.4 130.5±60.5 0.14   0.019   0.027 
Digit Span backward 4.8 ± 1.1  4.8 ± 1.2 4.2 ± 1.2 0.05   ns   0.047 
Memory and learning       
RAVLT learning 45.0 ± 7.5 39.9 ± 11.2 36.1 ± 11.7 0.12   0.023   ns 
RAVLT delayed  9.0  ± 3.1 6.8 ± 3.8 6.1 ± 4.1 0.11   0.004   ns 
Visuospatial functions       
Block Design  28.4 ± 8.2 27.9 ± 9.1 23.0 ± 8.2 0.06   ns   0.005 
Language       
Token Test  21.0 ± 1.2 19.4 ± 2.7 17.8 ± 3.7 0.19 <0.001   0.040 
ASLD Logical gram  23.3 ± 3.5 22.2 ± 3.4 20.0 ± 4.4 0.12   ns   0.045 
Executive functions       
PaSMO (seconds) 67.2 ± 24.4 80.1 ± 33.0 98.8 ± 44.3 0.16   0.050   0.008 
Weighted average (PCA) 1.97  ±  2.18 -0.36 ± 3.49 -1.98 ±3.56 0.21 <0.001   0.016 
 
 
 
p value=ANOVA, Adjusted p value=adjustment for multiple comparisons (Bonferroni), RAVLT=Rey 
Auditory Verbal Learning Test, ASLD=Assessment of Subtle Language Deficits, PaSMO=Parallel Serial 
Mental Operations,  
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There were also significant differences concerning MCI subtype between the 
groups. A larger proportion of MCI-vas belonged to the multiple domains 
non-amnestic group and a larger proportion of MCI-nov showed no 
significant impairment as compared to their age norm. 
 
 
Study III 
 
The objective of the study was to compare the neuropsychological profiles 
of MCI subjects with normal concentrations of total tau and Aß42 in 
cerebrospinal fluid (CSF) to MCI subjects with a deviating, AD-typical 
pattern, i.e. increased and decreased concentrations of the biomarkers.  
The participants consisted of 50 healthy controls, mean age 65 ± 6 years, 73 
MCI subjects with normal concentrations of T-tau and Aß42 (MCI-norm), 
mean age 61 ± 7 years and 73 MCI subjects with deviating concentrations of 
the biomarkers (MCI-dev), mean age 65 ± 7 years. Controls performed 
overall significantly better on the neuropsychological battery than the MCI 
groups. As to overall performance, MCI-norm and MCI-dev also differed 
significantly according to the PCA. The most clear-cut differences were seen 
on tests of speed/attention and episodic memory, as seen in table study III. 
When the MCI-dev subjects were grouped according to type of deviation in 
CSF into only high T-tau (N=35), only low Aß42 (N=15) and both high T-
tau and low Aß42 (N=23), the group with both high T-tau and low Aß42 had 
a tendency to perform slightly worse, whereas the other 2 groups performed 
quite similarly. 
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Study III                   Means and significance levels for neuropsychology 
Neuropsychological data Controls MCI-norm MCI-dev Eta2 Controls  
vs 
MCI-norm   
adjusted p 
Controls  
vs 
MCI-dev        
adjusted p 
MCI-norm 
vs 
MCI-dev 
adjusted p 
Weighted average 1.56 0.88 -2.13 0.22 0.006 <0.001 <0.001 
Speed and attention        
Digit Symbol 47.5 ±  9.8 46.5 ± 11.0 39.2 ± 10.9 0.11   0.204 <0.001*   0.012* 
Trail Making A 35.6 ± 11.3 38.4 ± 13.3 46.4 ± 17.7 0.12   0.016* <0.001*   0.054 
Trail Making B 81.8 ± 27.5 87.8 ± 34..9 114.5±48.6 0.12   0.102 <0.001*   0.012* 
Memory and learning        
RAVLT learning 44.5 ± 7.9 45.8 ± 8.6 37.2 ± 11.5 0.12   0.995 <0.001* <0.001* 
RAVLT delayed recall 8.8  ± 3.0 8.7 ± 2.9 6.2 ± 4.0 0.10   0.858 <0.001*   0.001* 
WLM delayed recall 21.1 ± 6.0 21.1 ± 7.0 16.2 ± 10.3 0.04   0.978  0.090   0.173 
RCF delayed recall 16.6 ± 6.0 16.5 ± 7.5 10.3 ± 7.1 0.14   0.488 <0.001* <0.001* 
RAVLT recognition 14.7 ± 0.5 14.6 ± 0.8 13.9 ± 1.8  0.08   0.851  0.001*   0.007* 
Language        
Token Test 21.1 ± 1.2 20.1 ± 1.7 18.8 ± 2.9 0.16  0.001* <0.001*   0.060 
Boston Naming Test 55.3 ± 2.9 53.5 ± 5.2 50.2 ± 6.9 0.14  0.007* <0.001*   0.050* 
 
 
 
 
 
When all 146 MCI subjects were subclassified into the 4 MCI subtypes, the 
majority of the 2 multidomain MCI groups, 59%, had high T-tau and/or low 
Aß42 concentrations, whereas only 33% of the amnestic and 28% of the 
single domain non-memory groups had deviating concentrations.  
 
 
 
Study IV 
 
Two years after baseline assessment, 34 subjects out of 209 were lost to 
follow up. Thus 175 subjects (84%) underwent follow-up examinations. The 
subjects lost to follow up did not differ on demographic variables from the 
others. Out of the 175 MCI subjects, 44 (25%) were diagnosed with 
dementia at follow-up, and 8 (4,5%) returned to normal function. The 
subjects who converted to dementia were significantly older, had shorter 
educations and scored lower on MMSE than the stable MCI group and those 
who returned to normal function.  
MCI-norm=MCI with normal concentrations of CSF T-tau and Aß42, MCI-dev= MCI with deviating 
concentrations of CSF T-tau and/or Aß42, *=mean difference is significant on 0.05 level, RAVLT=Rey Auditory 
Verbal Learning Test, WLM=Wechler’s Logical Memory, RCF=Rey Complex Figure 
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Aetiology and MCI subgroups 
 
The MCI subjects were classified into different aetiologies: vascular (N=56), 
neurodegenerative, based on Alzheimer-typical biomarkers (N=58), and no 
known aetiology (N=61). Out of the 44 dementias, 21 were AD, 12 MD, 8 
VaD, 2 non ultra descriptum (NUD) and one primary progressive aphasia 
(PPA), as seen in table study IV. The distribution of dementias and 
aetiologies in the different MCI subtypes are also presented.  
 
 
Study IV     Specific dementia diagnoses and distribution among MCI subtypes 
MCI subtype Vascular Degenerative AD  Mixed VaD  NUD  PPA  
aMCI (N=8) 1 3 0 0 0 0 0 
maMCI (N=62) 27 29 18 7 6 2 1 
mdMCI (N=30) 9 11 3 5 2 0 0 
sMCI (N=47) 10 10 0 0 0 0 0 
No impairment (N=28) 7 7 0 0 0 0 0 
 
As seen in the table, only the multiple domain MCI subjects converted to 
dementia. The MCI subtype with the highest proportion of converters was 
maMCI (56%), followed by mdMCI (30%). When classified by aetiology, 
the MCI group with AD biomarkers had the highest proportion of 
converters, 38%, while vascular disease had 34%. The MCI subtype with the 
highest proportion of subjects returning to normal function after 2 years was 
purely amnestic MCI.  
 
Likelihood ratios, sensitivities and specificities  
 
In order to find out which variables best predicted conversion to dementia, 
we calculated Likelihood Ratios (LR), sensitivities and specificities. The 
Likelihood Ratio (LR) is the likelihood that a patient with dementia – AD or 
MD/VaD – belongs to the specific MCI group, compared to the likelihood 
that the patient would belong to any of the other groups. Sensitivity and 
specificity are measures of accuracy. Sensitivity is the proportion of 
dementia patients who belong to the specific MCI group; specificity is the 
proportion of subjects without dementia who belong to another group. The 
highest LRs, sensitivities and specificities, for dementia in general, AD and 
MD/VaD were as follows: 
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 Dementia: maMCI: LR=49.6 (p<0.001), sensitivity 80%,      
specificity 79%  
 AD: maMCI: LR=26.0 (p<0.001), sensitivity 86%, specificity 71%  
 AD: maMCI/biomarkers: LR=30.0 (p<0.001), sensitivity 62%, 
specificity 92% 
 MD/VaD: vascular MCI: LR=22.4 (p<0.001), sensitivity 80% 
specificity 74% 
 MD/VaD: vas MCI/maMCI: LR=30.6 (p<0.001), sensitivity 65%, 
specificity 91% 
 
Thus, the highest LRs for both AD and MD/VaD were obtained by 
combining MCI subtype and aetiology.  
 
 
Neuropsychological variables 
 
We used a very basic evaluation method for the neuropsychological test 
battery: we reviewed the impaired results (<1.5 sd below mean of age 
appropriate controls) of the subjects who converted to dementia. Out of the 
21 AD patients, 18 had memory impairment at baseline. The 2 other 
cognitive domains with frequently impaired results were the visuospatial and 
language. Fourteen AD patients had both visuospatial and language 
impairment at baseline, 3 had only visuospatial impairment, and another 3 
only language impairment. For MD/VaD the executive and visuospatial 
were the domains with the highest proportion of impaired results, 14 out of 
20 subjects had impaired results in both, followed by speed/attention, 13 
subjects with impaired results. 
 
In order to identify the neuropsychological tests that were the strongest 
predictors of dementia in general and the specific dementia disorders (AD 
and Mixed/VaD), a Partial Least Squares Discriminant Analysis (PLS-DA) 
was performed on the data. According to the variable importance scores, no 
single test, or combination of tests, stood out for dementia in general, the 
most important variables being a number of memory and speed/attention 
variables (no figure shown). For AD, Wechsler’s Logical Memory, both 
immediate and delayed recall, together with the language comprehension 
test Token Test stood out. For MD/VaD, the executive test PaSMO tended to 
stand out, followed by some other executive, speed/attention, and learning 
and immediate – not delayed – recall variables. 
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Discussion   
 
The objective of the thesis was to investigate the cognitive profiles of 
different types of MCI and follow their course over time.  The results of the 
studies show that MCI is a very heterogeneous condition with significant 
impairment in all cognitive domains. One of the central findings of all 4 
studies was the importance of impairment other than memory in MCI. 
Memory impairment was not the most common kind of impairment, and 
only subjects who had additional impairment to memory, or other 
impairment than memory, converted to dementia. This finding contradicts 
the general views in the MCI literature, according to which memory 
impairment is the primary and most predictive symptom of MCI preceding 
dementia (DeCarli et al., 2004; Modrego, 2006; Petersen, 2000; Schmidtke 
& Hermeneit, 2008). Findings similar to ours have, however, lately been 
The figure shows that the strongest predictor of AD was the episodic memory test WLM 
delayed recall, followed by the language comprehension test Token Test. Also the memory 
variables RAVLT and RCF delayed recall contributed very significantly to the model. 
For MD/VaD the executive tests PaSMO and WCST were the best predictors, followed by the 
speed/attention tests Trailmaking A and B, Digit Symbol and RAVLT learning. Also WLM 
immediate recall and Token Test contributed significantly to the model. 
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reported (Alexopoulos et al., 2006; Herukka et al., 2007). The purely 
amnestic MCI (aMCI) has been quite rare throughout the studies and has 
also proved to have rather a benign prognosis, indeed more so than other 
single domain MCI types. Slightly less than half the MCI subjects in the 
studies exhibited significant episodic memory impairment, which also 
contradicts the notion of MCI typically being characterized by memory 
impairment. In fact 9% of the subjects without memory impairment 
converted to dementia – 3% to AD – over 2 years, which further 
demonstrates the importance of impairment other than memory in MCI. 
 
 
Cognitive profiles of different types of MCI 
 
One aim was to be able to differentiate between “benign” and “malign” 
forms of MCI, and identify different dementia disorders in their prodromal 
stages by means of cognitive profiles and aetiologies. Are the cognitive 
profiles of vascular and degenerative MCI essentially different? The 
differences between MCI with vascular disease (MCI-vas) and MCI with 
deviating biomarkers (MCI-dev) were in fact not impressive. When a direct 
comparison between the groups was made with a t-test (not presented in the 
results), only 2 tests came out significant: Digit Symbol and Block Design – 
MCI-dev performed better on both. Nevertheless, patterns of cognitive 
deficits can be perceived. MCI-vas tended consistently to perform more 
poorly on speed/attention and executive tests, even though the differences 
were not significant. More explicit differences were seen when the subjects 
who converted to dementia within 2 years were compared. Alzheimer’s 
disease (AD) and mixed dementia/vascular dementia (MD/VaD) patients 
had quite different cognitive profiles at baseline. In study IV the 
combination of memory, visuospatial and language impairment preceded 
AD, while speed/attention, visuospatial and executive impairment preceded 
MD/VaD. The memory performance of AD and MD/VaD also differed 
according to the PLS-DA. AD performed worse on delayed recall, while 
MD/VaD performed worse on learning and immediate recall. The same 
pattern was seen between MCI-vas and MCI-nov, and was in study II 
explained by poor learning strategies, which are executive deficits rather 
than episodic memory deficits as such. Taking into account that the vascular 
group consisted of a majority of mixed dementias –presumably with AD 
pathology –, the differences appear quite obvious.  
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“Benign” MCI 
 
As to more “benign” forms of MCI, a reasonable assumption would be that 
single domain subjects will have a more benign prognosis, since only 
multiple domain MCI subjects converted to dementia. A large proportion of 
the single domain MCI subjects, however, had either AD biomarkers or 
vascular disease, which suggests that they have pathological changes or 
processes in the brain. One conceivable explanation is that many subjects 
with impairment in only one domain are in earlier stages of dementia 
disorders, and will eventually convert to dementia. That may also apply for 
the subjects who did not show significant cognitive impairment compared to 
their age norm. Twenty-five percent of them had AD biomarkers and 25% 
significant vascular disease, indicating pathological changes or processes in 
the brain. Considering that only 2 MCI subjects without any known 
aetiology – vascular or degenerative according to biomarkers –converted to 
dementia, the best suggestion for identifying benign MCI would be single 
domain (memory or non-memory) MCI without any known aetiology. The 
MCI-norm (normal biomarkers) group that was compared to MCI-dev 
(Alzheimer-typical biomarkers) in study III consisted of subjects without 
any known aetiology and performed within all cognitive domains more like 
the healthy controls than like MCI-dev. Thus, a large proportion of those 
subjects, in all likelihood, have benign forms of MCI, caused by stress or 
other non-degenerative ill-health. 
 
 
MCI and vascular disease 
 
There are some reports indicating that vascular risk factors and vascular 
disease increase the risk both of AD and dementia in general, although there 
still is some discussion in the literature on the subject (Ravaglia et al., 2006; 
Sepe-Monti et al., 2007). The results presented in study II certainly support 
the notion that vascular disease affects cognition harmfully. MCI with 
vascular disease (MCI-vas) performed markedly worse than MCI without 
vascular disease, and even though the differences were small, MCI-vas 
rather consistently performed worst of all the groups on the test battery – 
only on WLM delayed recall did MCI with AD biomarkers (MCI-dev) 
perform slightly worse. The proportion of MCI-vas that converted to 
dementia was almost identical to the proportion of MCI-dev converters. 
Considering that the biomarkers are established dementia markers, the role 
of vascular disease as a risk factor for dementia seems obvious – even 
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considering that we have no information about possible biomarkers in the 
MCI-vas group. 
 
 
MCI and AD biomarkers  
 
Previous studies have found the AD biomarkers T-tau and Aß42 to be 
specifically linked to different cognitive functions. Elevated T-tau 
concentrations have primarily been associated with poor performance on 
episodic memory tests, whereas decreased Aß42 concentrations have been 
associated with poor general cognitive performance (Ivanoiu & Sindic, 
2005; Schoonenboom et al., 2005). This pattern was not found in the MCI 
subjects in studies III and IV. In study III the memory test scores of the 
subjects with high T-tau (MCI-tau) and low Aß42 (MCI-Aß) were almost 
identical. They also performed almost identically within the other cognitive 
domains. In study III both biomarkers were associated with generally poorer 
cognitive performance when compared to MCI subjects with normal 
biomarker concentrations. The only pattern that could be detected was that 
when both biomarkers were present, the subjects tended to perform slightly 
worse. It would seem that not one or the other of the biomarkers, but the 
biomarkers combined, are associated with markedly poorer memory and 
general cognitive performance. These results were confirmed by 
subclassification into MCI subgroups: 12 subjects with only high T-tau 
belonged to the amnestic groups and 15 to the non-amnestic. Thus, there was 
no association between biomarkers and specific kind of cognitive 
impairment or MCI subgroup. The combination of AD biomarkers and 
memory impairment with additional cognitive impairment, however, seemed 
to be the best predictor of AD: the combination of maMCI and biomarkers 
had the highest likelihood ratio for AD. 
 
 
Young dementia patients 
 
A recurring theme in all 4 studies has been that the subjects in the studies 
have been younger than in most comparable studies (Alexopoulos et al., 
2006; Amieva et al., 2004; Arnaiz et al., 2004; Grundman et al., 2004; 
Lautenschlager, Riemenschneider, Drzezga, & Kurz, 2001; Loewenstein et 
al., 2006; Luis et al., 2004; Sepe-Monti et al., 2007; Storandt, Grant, Miller, 
& Morris, 2002). That also is true for the subjects converting to dementia; 
the mean age of the dementia patients was lower than in most studies 
(Amieva et al., 2004; Geslani, Tierney, Herrmann, & Szalai, 2005; Herukka 
et al., 2007). Nevertheless, the distribution of dementia diagnoses in study 
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IV was quite similar to the majority of prevalence figures (Aggarwal & 
Decarli, 2007; Ferri et al., 2005). Almost 50% were AD, 27% MD and 18% 
VaD. These proportions support the suggestion that MD is one of the most 
common forms of dementia (Langa et al., 2004; Nagga et al., 2004). The 
mean age of the AD patients was at the time of diagnosis below 65, which 
means that a large proportion of them were early onset AD. That is reflected 
in the cognitive profiles of the AD patients, which were the typical “early 
onset profiles” described in the literature, with predominantly 
“temporoparietal symptoms”, that is visuospatial and language deficits 
(Blennow & Wallin, 1992; Reid et al., 1996). The cognitive profile of 
MD/VaD was also rather typical for subcortical VaD: poor performance in 
the speed/attention and executive domains (Roman et al., 2002; Roman & 
Royall, 1999). The fact that MD patients according to the literature 
cognitively resemble AD more than VaD (Schmidtke & Hull, 2002) raises 
the question about how great the impact of vascular disease early in the 
course of the disease is. The finding that MD and VaD seemingly had a 
reasonably uniform cognitive profile supports the notion of including MD in 
the VaD diagnosis (Nagata et al., 2007). Considering that the patients in 
study IV were quite clearly younger than in most other studies, the question 
is whether the dementia diagnosis today is given earlier than before. Since 
the decisive criterion for dementia is that the cognitive impairment should be 
of such a magnitude that the patient no longer is able to manage his or her 
everyday life without support, the hypothesis can not be ruled out. There is 
much evidence that we today live in a society more cognitively demanding 
than ever before, as stated above. Consequently, the demands on a patient 
with cognitive decline would increase, the cognitive deficits would be 
apparent earlier than before and the patient would lose independence at an 
earlier stage, resulting in a dementia diagnosis.  
 
 
Importance of the findings/conclusions 
 
Considering the fast increasing number of patients suffering from dementia, 
the rising costs, and new emerging therapies, the need for early and exact 
diagnostic methods is obvious. One of the problems many memory clinics 
face is the increasing number of patients with cognitive impairment caused 
by conditions other than prodromal dementia – stress, depression and other 
ill-health. These patients often fear that they have early signs of a dementia 
disorder and sometimes live with that fear for years. Much suffering could 
be avoided with more exact diagnostic methods. Both in the interest of the 
society in large and the individual patient, this task is urgent. I believe that a 
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comprehensive neuropsychological examination is an indispensable part of 
more exact diagnostic methods. The MCI subtypes are to some degree useful 
but need to be refined, with information about the specific cognitive 
domains that are impaired. Multiple domains amnestic MCI obtained the 
highest Likelihood ratio for dementia in general – unspecific cognitive 
impairment predicting unspecific dementia. I believe that cognitive profiles 
– information about which cognitive domains are impaired – is an important 
step toward a more exact early diagnosis of dementia. I find the high 
Likelihood Ratios and reasonable sensitivities and specificities for AD and 
MD/VaD that were obtained by combining MCI subtype and aetiology 
encouraging. I believe that the prognostic accuracy of that combination can 
be much increased when a larger number of patients are followed over a 
longer period of time. Thus, in my view, a comprehensive 
neuropsychological assessment providing more exact and refined cognitive 
profiles will make a crucial contribution when diagnosing dementia 
disorders in their earliest manifestations. 
 
 
Limitations 
 
As stated in the introduction, the ambition of a cognitive psychologist is to 
generate models of cognitive processes in order to compare them to data 
from humans. There, in all likelihood, are many important cognitive 
functions and processes that we thus far do not have the adequate tests to 
measure. One obvious such function is prospective episodic memory – to 
remember to remember, or to remember what one has planned to do. My 
impression is that a substantial proportion of the patients at our memory 
clinic experience prospective memory problems, but we do not have a test to 
measure those problems with. That may be one reason why only hardly half 
the patients had significantly reduced results on the memory tests. I do 
consider the neuropsychological battery both comprehensive and well 
balanced, but certainly it also has its limitations. With a different 
combination of tests, the results may have had been different. 
 
MCI and dementia diagnostics is not an exact science. Even though we have 
applied specific research criteria, there always is some degree of 
arbitrariness, both in the inclusion process and the specific dementia 
diagnoses. Considering the slightly inexact inclusion criteria, some subjects 
may have been included in the study with not much more than subjective 
cognitive complaints. Furthermore, the subgroupings – both in terms of 
aetiology and MCI subclassification – may be somewhat inexact. When 
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subgroupings and –classifications are made by means of cut-off scores, there 
always will be some degree of arbitrariness. Nevertheless, considering the 
results, all in all both inclusion, subgroupings and diagnoses seem to be as 
stringent as can be required. 
 
 
Future directions 
 
As suggested above, the next step will be to evolve the MCI concept by 
applying different cognitive profiles to it. How many different profiles will 
make clinical sense? One with mainly language and visuospatial deficits, 
and one with speed/attention and executive deficits? Can we identify 
additional patterns, for example a pattern typical for stress or depression; a 
benign, reversible MCI profile? I believe that there still is much to do in 
terms of exploring cognitive profiles for different conditions characterized 
by cognitive ill-health. 
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